tradmap

NAII NATURAL ALTERNATIVES INTERNATIONAL INC

$1.11 +1.83%

Data as of close

Healthcare · Medicinal Chemicals & Botanical Products

NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $6 million. Shares last traded at $1.11, 77.6% below their 52-week high. Over the past year the stock is down 68.3%. Net profit margin is -14.5%, below the peer median of -8.8%. Revenue declined 77.1% year over year.

Market Cap
$6M
Shares Out
5.8M
EPS (TTM)
-$3.43
P/E (TTM)*
—
P/S Ratio
0.05
P/B Ratio
0.13
Dividend / Share
—
Dividend Yield
—
52-Week High
$4.96
52-Week Low
$1.07
Volume (venue)
61
Avg Vol (3m, venue)
652.254

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-7.11%
1M
-23.45%
3M
-50.00%
6M
-58.58%
YTD
-68.51%
1Y
-68.29%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
31.47
SMA (50)
$1.68
SMA (200)
$2.59
Price vs SMA50
-33.81%
Price vs SMA200
-57.11%
ATR (14)
$0.08

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$143M
Net Income
-$21M
Gross Margin
6.3%
Operating Margin
-13.2%
Net Margin
-14.5%
Return on Equity
-41.4%
Return on Assets
-16.4%
Current Ratio
1.73
Debt / Equity
0.00
Revenue Growth (YoY)
-77.1%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q4 2026 (derived) -$2.24 2026-09-28
FY 2026 -$3.43 2026-09-28
Q3 2026 -$0.72 2026-05-19
Q2 2026 -$0.42 2026-02-13
Q1 2026 -$0.05 2025-11-12
Q4 2025 (derived) -$1.21 2025-09-23

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Medicinal Chemicals & Botanical Products peers

NAII vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close

P/S vs peers
0.05 / 0.58 med
-92% discount
Net margin vs peers
-14.5% / -8.8% med
below median
1–14 of 14
DFTXDefinium Therapeutics, Inc.$4.4B———-10.70%
RGCRegencell Bioscience Holdings Ltd$3.1B———-5.00%
TRLVTrulieve Cannabis Corp.$2.1B—1.88-41.8%+8.19%
CRONCronos Group$1.2B17.646.8939.1%+1.52%
TLRYTilray Brands$375M—0.39-17.1%+0.40%
SNDLSNDL Inc.$337M———+2.81%
CGCCanopy Growth$288M—1.37-80.0%+4.07%
USNAUSANA HEALTH SCIENCES INC$271M—0.30-2.4%+2.69%
ACBAurora Cannabis$237M———+3.94%
GLASGlass House Brands Inc.$192M—1.05-16.3%+6.85%
NAGENiagen Bioscience, Inc.$190M11.881.4712.4%+2.56%
MDWDMediWound Ltd.$173M———+1.35%
FTLFFITLIFE BRANDS, INC.$78M12.450.776.2%+4.69%
BTMDbiote Corp.$33M5.560.183.2%+1.79%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.